The HTAC recommends the emergency use of SARS-CoV-2 Vaccine (Vero cell), Inactivated [CoronaVac] (commonly known as Sinovac) to prevent COVID-19 for persons aged 18 to 59 with low risk of exposure to the disease, and within identified priority groups Sinovac COVID-19 Vaccine under Emergency Use The emergency use authorization of the Food and Drug Administration continue reading : HTAC Guidance for the General Public: COVID-19 Vaccine Sinovac
HTAC Recommends COVID-19 Vaccine Janssen Under Emergency Use for Reducing COVID-19 Risk in Persons Aged 18 and Older
Date of publication: April 30, 2021 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of COVID-19 Vaccine Janssen. This assessment follows the continue reading : HTAC Recommends COVID-19 Vaccine Janssen Under Emergency Use for Reducing COVID-19 Risk in Persons Aged 18 and Older
Evidence brief for 24 April to 30 April 2021
For the period of 24 April to 30 April 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 24 April to 30 April 2021
Evidence brief for 17 April to 23 April 2021
For the period of 17 April to 23 April 2021 Reviewed by: Department of Health (DOH) – Health Technology Assessment Unit (HTAU) Document Link: 17 April to 23 April 2021